JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
The relationship between hepatocellular carcinoma and Resolvin D1
Abstract
Aims: Liver cancer is the second most common cause of cancer death, and hepatocellular carcinoma (HCC) is the most common hepatic primary tumor. Hepatocellular carcinoma develops based on inflammation in the cirrhotic liver. The aim of our study was to determine the relationship between the decrease in Resolvin D1, the lipid mediator involved in the resolution, and hepatocarcinogenesis.
Methods: Thirty patients with HCC, thirty patients with cirrhosis, and thirty healthy subjects followed in our clinic between March 2018 and June 2019 were included in the study. Routine laboratory test results of the patients were recorded from the institutional database. Resolvin D1 and other parameters of the study groups were compared.
Results: The Resolvin D1 levels were found to be significantly different from each other group, with the ranking as follows: the HCC group (1.71 ± 1.46 ng/ml)< the cirrhotic group (3.63 ± 2.92 ng/ml)< the healthy control group (6.24 ± 3.18 ng/ml). Moreover, Resolvin D1 levels were negatively correlated with ?-fetoprotein (AFP) level and tumor stage.
Conclusion: Reduced lipid mediators that aid in the resolution process cause an increase in pro-inflammatory cytokines involved in the development of hepatocellular carcinoma. A decrease in Resolvin D1 may serve as a biomarker contributing to the diagnosis of progression to HCC in cirrhotic patients by triggering chronic inflammation and hepatocarcinogenesis.

Keywords : Hepatocellular carcinoma, cirrhosis, pro-inflammatory cytokines, AFP, Resolvin D1

Download Article


1. Shimozawa N, Hanazaki K. Longterm prognosis after hepatic resectionfor small hepatocellular carcinoma. J American Coll Surgeons.2004;198(3):356-365.
2. Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patientswith hepatitis B and hepatocellular carcinoma. Clin GastroenterolHepatol. 2011;9(1):64-70.
3. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma:Epidemiology, etiology, and carcinogenesis. J Carcinogene. 2017;16.
4. Galle PR, Forner A, Llovet JM, ET AL. EASL clinical practiceguidelines: management of hepatocellular carcinoma. J Hepatol.2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019
5. Jin K, Li T, S&aacute;nchez-Duffhues G, Zhou F, Zhang L. Involvement ofinflammation and its related micrornas in hepatocellular carcinoma.Oncotarget. 2017;8(13):22145.
6. Janakiram NB, Mohammed A, Rao CV. Role of lipoxins, resolvins, andother bioactive lipids in colon and pancreatic cancer. Cancer MetastasRev. 2011;30:507-523.
7. Krishnamoorthy S, Recchiuti A, Chiang N, et al. Resolvin D1 bindshuman phagocytes with evidence for proresolving receptors. ProceedNati Aca Sci. 2010;107(4):1660-1665.
8. Qu Q, Xuan W, Fan GH. Roles of resolvins in the resolution of acuteinflammation. Cell Bio Internat. 2015;39(1):3-22.
9. Lu Y, Xu Q, Yin G, Xu W, Jiang H. Resolvin D1 inhibits the proliferationof lipopolysaccharide-treated HepG2 hepatoblastoma and PLC/PRF/5hepatocellular carcinoma cells by targeting the MAPK pathway.Experim Therape Med. 2018;16(4):3603-3610.
10. Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary livercancer and underlying etiologies from 1990 to 2015 at the global,regional, and national level: results from the global burden of diseasestudy 2015. JAMA Oncol. 2017;3(12):1683-1691.
11. Recchiuti A. Resolvin D1 and its GPCRs in resolution circuits ofinflammation. Prostagland &amp; Other lip Mediat. 2013;107:64-76.
12. Navarini L, Bisogno T, Margiotta DPE, et al. Role of the specializedproresolving mediator resolvin D1 in systemic lupus erythematosus:preliminary results. J Immun Res. 2018.
13. Fedirko V, McKeown-Eyssen G, Serhan CN, et al. Plasma lipoxinA4 and resolvin D1 are not associated with reduced adenoma risk ina randomized trial of aspirin to prevent colon adenomas. MolecuCarcinogene. 2017;56(8):1977-1983.
14. Morshedzadeh N, Saedisomeolia A, Djalali M, Eshraghian MR,Hantoushzadeh S, Mahmoudi M. Resolvin D1 impacts on insulinresistance in women with polycystic ovary syndrome and healthywomen. Diabet Metab Synd: Clin Res Rev. 2019;13(1):660-664.
15. Zhuang Q, Meng Q, Xi Q, Wu G. Association of serum inflammatorycytokines and Resolvin D1 concentration with pathological stage ofcolon cancer. Zhonghua wei chang wai ke za zhi= Chinese J GastrointestiSurg. 2018;21(11):1285-1290.
16. Cata JP, Velasquez JF, Ramirez MF, et al. Inflammation and pro-resolution inflammation after hepatobiliary surgery. World J SurgiOncol. 2017;15(1):1-6.
17. Kuang H, Hua X, Zhou J, Yang R. Resolvin D1 and E1 alleviate theprogress of hepatitis toward liver cancer in long-term concanavalina-induced mice through inhibition of NF-&kappa;B activity. Oncol Rep.2016;35(1):307-317.
18. Sulciner ML, Serhan CN, Gilligan MM, et al. Resolvins suppresstumor growth and enhance cancer therapy. J Experimen Med.2018;215(1):115-140.
19. Kang J-W, Lee S-M. Resolvin D1 protects the liver from ischemia/reperfusion injury by enhancing M2 macrophage polarizationand efferocytosis. Biochim Biophy Acta (BBA)-Molec Cell Biol Lip.2016;1861(9):1025-1035.
20. Lee HJ, Park MK, Lee EJ, Lee CH. Resolvin D1 inhibits TGF-&beta;1-inducedepithelial mesenchymal transition of A549 lung cancer cells via lipoxinA4 receptor/formyl peptide receptor 2 and GPR32. Internat J BiochemCell Biol. 2013;45(12):2801-2807.
21. Deyama S, Ishikawa Y, Yoshikawa K, et al. Resolvin D1 and D2reverse lipopolysaccharide-induced depression-like behaviors throughthe mTORC1 signaling pathway. Internat J Neuropsychopharma.2017;20(7):575-584.
22. Kirchner G, Kirovski G, Hebestreit A, et al. Epidemiology and survivalof patients with hepatocellular carcinoma in Southern Germany.Interna J Clin Experim Med. 2010;3(2):169.
23. Saito H, Masuda T, Tada S, et al. Hepatocellular carcinoma in keioaffiliated hospitals&mdash;diagnosis, treatment, and prognosis of thisdisease&mdash;. Keio J Med. 2009;58(3):161-175.
24. Yan L, Chen Y, Zhou J, Zhao H, Zhang H, Wang G. Diagnostic value ofcirculating cell-free DNA levels for hepatocellular carcinoma. Internat JInfect Dis. 2018;67:92-97.
Article available in :
Volume 1, Issue 4, 2023
Page : 96-101
https://doi.org/10.51271/JCHOR-0021
Article Information
Received : 02 Kas 2023
Accepted : 28 Kas 2023
Published : 30 Kas 2023
Corresponding Author :

Züleyha Erdin: Department of Internal Medicine, Abant İzzet Baysal University Hospital, Bolu, Turkey

[email protected]
Citation : Erdin Z, Gül Ö, Ergül B, et al. The relationship between hepatocellular carcinoma and resolvin D1. J Curr Hematol Oncol Res. 2023;1(4):96-101.

Read: 399
Download : 636
Cited: 0
_Footer